Figure S2 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

Authors :: Barbra J. Sasu
Javier Chaparro-Riggers
Pavel Strop
Arvind Rajpal
David Shelton
Jeffrey L. Wolf
Thomas G. Martin
Bernard Buetow
Ingrid Pardo
Michael Mirsky
Bora Han
Bing Kuang
Allison G. Chunyk
Kevin C. Lindquist
Yik Andy Yeung
Thomas J. Van Blarcom
Sherman M. Chin
Russell G. Dushin
Marjorie Bateman
Santiago Farias
Kathy Delaria
Wei Chen
Edward Pascua
Cris Kamperschroer
Laura Aschenbrenner
Tao Geng
Amy Chen
Yi Zhang
Tracy C. Kuo
Siler H. Panowski
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: BCMA bispecific is activity in the presence of soluble BCMA and APRIL.

Tools